ModeX Therapeutics
ModeX Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the tetraspecific T-cell engagers MDX2001 and MDX2003 in biliary tract cancer, cervical cancer, colorectal cancer and endometrial cancer.
Overview
ModeX Therapeutics develops multispecific antibodies and nanoparticle vaccines for cancer and infectious disease. Its oncology pipeline includes MDX2001 (cMET x Trop2 x CD3 x CD28) for solid tumours and MDX2003 (CD19 x CD20 x CD3 x CD28) for B-cell leukaemia and lymphoma, both tetraspecific T-cell engagers. It is a wholly owned subsidiary of OPKO Health. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06239194 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors) and NCT07249905 (phase 1/2, Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
- JournalClinical colorectal cancer
Shares Biliary tract cancer (cholangiocarcinoma), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
- CollectionLymphoma Research Foundation (LRF)
Shares Waldenström macroglobulinaemia, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Study of MT-4561 in Patients With Various Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TrialStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Shares Waldenström macroglobulinaemia, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
- JournalJournal of gastrointestinal cancer
Shares Biliary tract cancer (cholangiocarcinoma), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
- TrialStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Shares Biliary tract cancer (cholangiocarcinoma), Endometrial cancer, Cervical cancer.